Q-omics provides the consensus-scored ZNF648 profile across patient tissues and cancer cell-line models. ZNF648 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ZNF648 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, ZNF648 RNA expression shows 12,428 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, LIHC, and TGCT as cancer lineages where ZNF648 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF648 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF648 survival associations across molecular data types. ZNF648 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF648 RNA expression–survival associations across cancer types. High ZNF648 expression shows unfavorable associations in DLBC, UCEC, LGG, KIRC, KIRP and COAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for ZNF648 RNA expression.
This table summarizes ZNF648 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF648. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF648 shows lower tumor expression in KICH and COAD and higher tumor expression in LIHC, LUAD, KIRP and LUSC. The LIHC box plot shows higher ZNF648 RNA expression in tumor versus normal tissue (log2 FC = +0.876, t-test p < 0.001).
This table shows molecular features associated with ZNF648 in patient tissues and cancer cell lines. In patient samples, ZNF648 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF648 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
